Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells
DOI:
https://doi.org/10.18433/jpps30493Abstract
Purpose: Toll-like receptor 4 (TLR4) is over-expressed in breast tumors and thus contributing to the tumor progression and metastasis. Natural products have drawn attention in cancer immunotherapy due to their various biological activities. Curcumin is well investigated in different types of cancer. However, the mechanisms underlying its anti-inflammatory actions have not been extensively elucidated. For this purpose, we explored the inhibitory effects of curcumin on lipopolysaccharide (LPS)-induced TLR4 dependent TRIF signaling pathway in two subtypes of breast cancer cell lines (MCF-7 and MDA-MB-231) in this study. Methods: In this context, the cytotoxicity of curcumin and LPS alone and the combination of curcumin with LPS on these cells was evaluated by WST-1 assay. The expression level of TLR4 and the release of type I interferon (IFN) levels were determined after treatment with curcumin and/or LPS by RT-PCR and ELISA analysis, respectively. Furthermore, the subcellular localization of TLR4 and interferon regulatory factor 3 (IRF3) were detected by immunofluorescence analysis. Results: Curcumin treatment suppressed breast cancer cells viabilities and the activation of TLR4-mediated TRIF signaling pathway by the downregulation of TLR4 and IRF3 expression levels and the inhibition of type I IFN (IFN-α/β) levels induced by LPS. However, curcumin was more efficient in MDA-MB-231 cells than MCF-7 cells owing to its greater inhibitory efficacy in the LPS- enhanced TLR4 signaling pathway. Furthermore, IFN-α/β levels induced by TLR4 and IRF3 were decreased in these cells following curcumin treatment. Conclusions: Consequently, these results demonstrated that the activation of LPS stimulated TLR4/TRIF/IRF3 signaling pathway was mediated by curcumin in breast cancer cells, in vitro. However, more studies are necessary to examine the curcumin’s anti-inflammatory activities on TLR4/MyD88/NF-κB as well as other signaling pathways downstream of TLRs in breast cancer.Downloads
References
Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr, 2004; 44:97-111.
Goel A. Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer, 2010; 62:919–930. DOI: 10.1080/01635581.2010.509835.
Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 2011; 16:4567-4598. DOI: 10.3390/molecules16064567.
Calaf GM, Ponce-Cusi R, Carrión F. Curcumin and paclitaxel induce cell death in breast cancer cell lines. Oncol Rep, 2018; 40(4):2381-23885. DOI: 10.3892/or.2018.6603.
Fahey AJ, Adrian Robins R. Constantinescu CS. Curcumin modulation of IFN‐β and IL‐12 signalling and cytokine induction in human T cells. J Cell Mol Med, 2007; 11(5):1129-1137. DOI: 10.1111/j.1582-4934.2007.00089.x.
Boozari M, Butler AE, Sahebkar A. Impact of curcumin on toll‐like receptors. J Cell Physiol, 2019;1–12. DOI: 10.1002/jcp.28103.
Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol, 2005; 17:1–14. DOI: 10.1093/intimm/dxh186.
Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol, 2003; 21:335-76. DOI: 10.1146/annurev.immunol.21.120601.141126.
Janeway CA. Jr. Approaching the a symptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol, 1989; 54:1–13. doi:10.1101/SQB.1989.054.01.003.
Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate cancer. Front Immunol, 2014; 23:5-352. DOI: 10.3389/fimmu.2014.00352.
Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med, 2009; 13:6(1):e10. doi:10.1371/journal.pmed.1000010.
Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology, 2007; 133:1869–1881. DOI: 10.1053/j.gastro.2007.09.008.
Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther, 2008; 7(11):3642-53. doi: 10.1158/1535-7163.
He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol, 2007; 44:2850–2859. DOI: 10.1016/j.molimm.2007.01.022.
Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 2007; 67:774–781. DOI: 10.1002/pros.20562.
Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 1998; 282:2085-8. DOI: 10.1126/science.282.5396.2085.
Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H, Zhu X. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res, 2010; 10:29:92. doi: 10.1186/1756-9966-29-92.
Yang H, Wang B, Wang T, Xu L, He C, Wen H, Yan J, Su H, Zhu X. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS One, 2014; 9:9(10):e109980. doi: 10.1371/journal.
Kim J, Durai P, Jeon D, Jung ID, Lee SJ, Park YM, Kim Y. Phloretin as a Potent Natural TLR2/1 Inhibitor Suppresses TLR2-Induced Inflammation. Nutrients, 2018; 5:10(7), pii: E868. DOI: 10.3390/nu10070868.
Molteni M, Bosi A, Rossetti C. Natural Products with Toll-Like Receptor 4 Antagonist Activity. Int J Inflam, 2018; 1:2859135. doi:10.1155/2018/2859135.
Gao H, Liu X, Sun W, Kang N, Liu Y, Yang S, Xu QM, Wang C, Chen X. Total tanshinones exhibits anti-inflammatory effects through blocking TLR4 dimerization via the MyD88 pathway. Cell Death Dis, 2017; 17:8(8):e3004. doi:10.1038/cddis.2017.389.
Chung HJ, Koh W, Kim WK, Shin JS, Lee J, Lee SK, Ha IH. The Anti-Inflammatory Effects of Shinbaro3 Is Mediated by Downregulation of the TLR4 Signalling Pathway in LPS-Stimulated RAW 264.7 Macrophages. Mediators Inflamm, 2018; 5:2018:4514329. doi: 10.1155/2018/4514329.
Arreola R, Quintero-Fabián S, López-Roa RI, Flores-Gutiérrez EO, Reyes-Grajeda JP, Carrera-Quintanar L, Ortuño-Sahagún D. Immunomodulation and anti-inflammatory effects of garlic compounds. J Immunol Res, 2015;2015:401630. doi:10.1155/2015/401630.
Patel SS, Acharya A, Ray RS, Agrawal R, Raghuwanshi R, Jain P. Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr, 2019; 11:1-53. doi: 10.1080/10408398.2018.1552244.
Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets, 2011; 12(3):332-47. DOI : 10.2174/138945011794815356
Lin JK. Molecular targets of curcumin. Adv Exp Med Biol, 2007; 595:227-43. DOI: 10.1007/978-0-387-46401-5_10.
Banik U, Parasuraman S, Adhikary AK, Othman NH. Curcumin: the spicy modulator of breast carcinogenesis. J Exp Clin Cancer Res, 2017; 36(1):98. doi: 10.1186/s13046-017-0566-5.
Sun XD, Liu XE, Huang DS. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Rep, 2012; 6(6):1267-70. doi: 10.3892/mmr.2012.1103.
Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett, 2002; 512(1-3):334-40. https://doi.org/10.1016/S0014-5793(02)02292-5.
Liu D, Chen Z. The effect of curcumin on breast cancer cells. J Breast Cancer, 2013; 16 (2):133–137. doi:10.4048/jbc.2013.16.2.133
Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact, 2009; 7:181(2):263-71. doi:10.1016/j.cbi.2009.06.012.
Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors, 2013; 39(1):27-36. doi: 10.1002/biof.1065.
Sa G, Das T. Anti-cancer effects of curcumin: cycle of life and death. Cell Div, 2008; 3:14. doi: 10.1186/1747-1028-3-14.
Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis, 2003; 24(7):1199-208. DOI: 10.1093/carcin/bgg082.
Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol, 2008; 76(11):1340-51. doi:10.1016/j.bcp.2008.07.031.
Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol, 2011; 30(1):16-34. doi: 10.3109/08830185.2010.529976.
O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol, 2007; 7(5):353-64. DOI: 10.1038/nri2079.
Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol, 2006; 6(9):644-58. DOI: 10.1038/nri1900.
O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol, 2006; 18(1):3-9. DOI: 10.1016/j.coi.2005.11.012.
De Nardo D. Toll-like receptors: Activation, signalling and transcriptional modulation. Cytokine, 2015; 74(2):181-9. doi: 10.1016/j.cyto.2015.02.025.
So EY, Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci, 2010; 6(7):675-681. doi:10.7150/ijbs.6.675.
González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JM, Vizoso FJ. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer, 2010; 10:665. doi: 10.1186/1471-2407-10-665.
Youn HS, Lee JY, Saitoh SI, Miyake K, Kang KW, Choi YJ, Hwang DH. Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by (-)-epigallocatechin-3-gallate, a polyphenol component of green tea. Biochem Pharmacol, 2006; 72(7):850-9. DOI: 10.1016/j.bcp.2006.06.021.
Lee JK, Kim SY, Kim YS, Lee WH, Hwang DH, Lee JY. Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. Biochem Pharmacol., 2009; 77(8):1391-400. doi: 10.1016/j.bcp.2009.01.009.
Ahn SI, Lee JK, Youn HS. Inhibition of homodimerization of toll-like receptor 4 by 6-shogaol. Mol Cell, 2009; 27(2): 211-215. https://doi.org/10.1007/s10059-009-0026-y.
Huang T, Chen Z, Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells. Oncol Rep, 2013; 29(1):117-24. doi: 10.3892/or.2012.2080.
Gradisar H, Keber MM, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol, 2007; 82(4):968-74. DOI: 10.1189/jlb.1206727.
Wang Z, Chen G, Chen L, Liu X, Fu W, Zhang Y, Li C, Liang G, Cai Y. Insights into the binding mode of curcumin to MD-2: studies from molecular docking, molecular dynamics simulations and experimental assessments. Mol Biosyst. 2015; 11(7):1933-8. doi: 10.1039/c5mb00085h.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev, 2004; 202:275-93.
Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel), 2011; 3(4):3856–3893. doi:10.3390/cancers3043856
Downloads
Published
How to Cite
Issue
Section
License
This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.
CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.
